Liquid Biopsy Market Report 2025

This Liquid Biopsy market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The liquid biopsy market size has grown rapidly in recent years. It will grow from $1.25 billion in 2024 to $1.46 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period can be attributed to advances in cancer research, non-invasiveness, personalized medicine, regulatory approvals, early cancer detection.

The liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $2.76 billion in 2029 at a compound annual growth rate (CAGR) of 17.2%. The growth in the forecast period can be attributed to expanding applications, cancer monitoring, emerging technologies, companion diagnostics, biomarker discovery. Major trends in the forecast period include cancer detection and monitoring, therapeutic monitoring, minimal residual disease (mrd) monitoring, liquid biopsy in non-oncological applications.

The rise in government funding for cancer detection advancements is a major factor driving the growth of the liquid biopsy market. This funding is largely due to the increasing global cancer burden, the need for early detection to improve treatment outcomes, and the emphasis on reducing healthcare costs through innovative diagnostic technologies. Government support aids liquid biopsy development by accelerating research, funding clinical trials, and promoting the use of advanced, non-invasive diagnostic methods for early cancer detection and personalized treatment approaches. For example, in October 2024, gov.UK, a UK-based government website, reported that £118 million ($150.38 million) was allocated to UK Research and Innovation, including £54 million from the government and £64 million ($81.55 million) from partners. Therefore, the rise in government funding for cancer detection advancements is propelling the growth of the liquid biopsy market.

The rising incidence of cancer is expected to drive the expansion of the liquid biopsy market. Cancer, characterized by uncontrolled cell growth and invasive tendencies, is detectable through liquid biopsy methods. These techniques identify cancer-specific biomarkers like circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in a patient's blood sample, enabling non-invasive diagnosis and monitoring. For instance, the American Cancer Society Inc. projects an increase in newly diagnosed cancer cases in the USA, from over 1,918,030 cases in 2022 to an estimated 1,958,310 cases in 2023. This surge in cancer prevalence serves as a driver for the liquid biopsy market's growth.

Businesses are rapidly adapting to new market demands and are notably prioritizing the launch of cutting-edge products within the liquid biopsy sector. This initiative aims to address the ever-increasing requirement for liquid biopsy products and services, augmenting their revenue and establishing a competitive advantage over their competitors. As an example, in June 2023, Laboratory Corporation of America Holdings, a US-based healthcare company, introduced Labcorp Plasma Focus, a liquid biopsy test engineered for identifying cancer-associated biomarkers in individuals with advanced or metastatic solid tumors. The test leverages the analysis of cell-free DNA (cfDNA) present in a patient's blood sample, constructing a detailed genomic profile of their tumor. This approach equips oncologists to refine patient healthcare management by creating personalized and precisely targeted therapy strategies.

Prominent companies involved in the liquid biopsy market are dedicating their efforts to the development of extensive liquid biopsy panels to gain a competitive edge. These extensive liquid biopsy panels serve as advanced diagnostic tools, analyzing various biomarkers within a patient's blood sample to detect and monitor a wide array of diseases, notably cancer. For instance, in June 2022, Tempus Labs Inc., a US-based technology company focused on precision medicine through artificial intelligence, announced the introduction of xF+, the most expansive liquid biopsy panel clinically available. This panel covers a broader range of genes, including single nucleotide variants, indels in all genes, and an expanded coverage of translocations, gene rearrangements, and copy number variants. Additionally, the xF+ panel evaluates blood-based tumor mutational burden (bTMB) and microsatellite instability, providing essential predictive biomarkers for various cancer immunotherapies' efficacy.

In February 2024, Veracyte Inc., a US-based diagnostics company, acquired C2i Genomics Inc. for $70 million. Through this acquisition, Veracyte aims to enhance its diagnostics platform by integrating whole-genome minimal residual disease (MRD) capabilities. This deal allows Veracyte to leverage C2i's AI-driven technology to improve the detection of circulating tumor DNA from blood samples, with the goal of expanding its cancer care offerings. C2i Genomics Inc., also based in the US, specializes in AI-powered liquid biopsy for cancer diagnostics.

A liquid biopsy is a non-invasive and relatively painless alternative to surgical biopsies, enabling healthcare professionals to obtain valuable information about tumors through a simple blood sample. It is a diagnostic test conducted on blood to identify the presence of cancerous cells, often used for early-stage cancer detection.

The primary product types within the liquid biopsy market encompass assay kits, instruments, and services. Assay kits provide the necessary reagents and components for conducting analytical tests, which are used in various industries such as food, cereals and dietary fiber, dairy, analytical laboratories, animal feed and nutrition, biofuels, biotechnology, wine, malting and brewing, and research. Liquid biopsy has numerous clinical applications, including early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring, which are utilized by reference laboratories, hospitals and physician laboratories, and academic and research centers in the field of orthopedics and oncology, among others.

The liquid biopsy market research report is one of a series of new reports that provides liquid biopsy market statistics, including liquid biopsy industry, regional shares, competitors with a liquid biopsy market share, detailed liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the liquid biopsy industry. This liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the liquid biopsy market include QIAGEN NV, Roche Diagnostics Ltd., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Guardant Health Inc., Thermo Fisher Scientific Inc., Menarini Silicon Biosystems, Biocept Inc., Janssen Diagnostics LLC, Trovagene Inc., Fraunhofer-Gesellschaft, MDX Health SA, Agilent Technologies Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Quantum Biosystems Inc., Menarini Silicon Biosystems Inc., Pathway Genomics Corporation, Sysmex Corporation, Janssen Global Services LLC, Natera Inc., ANGLE PLC, Bio Techne Corp, Biodesix Inc., CellMax Inc., CIRCULOGENE, Exact Sciences Corporation, Epic Sciences Inc., Exosome Diagnostics Inc., GRAIL Inc., Guardant Health AMEA, Inivata Ltd., NIPD Genetics, Oncocyte Corporation, Personal Genome Diagnostics Inc., RainDance Technologies Inc., Thrive Earlier Detection Corp.

North America was the largest region in the liquid biopsy market in 2024. Western Europe was the second largest region in the liquid biopsy market. The regions covered in the liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The liquid biopsy market includes revenues earned by entities by DNA collection tubes, tests, and reagents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.